ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CXCR4

CXCR4

概要

Name:C-X-C motif chemokine receptor 4
Target Synonym:NPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
CX4-H52D3 Human Human CXCR4 Full Length Protein, Flag,His Tag (Detergent)
CX4-H52D3-structure
CX4-H5219 Human Human CXCR4 / CD184 Full Length Protein (VLP)
CX4-H5269 Human Human CXCR4 / CD184 Protein, Fc Tag
CX4-H5269-structure
CX4-H5269-sds
ACRO Quality

生物活性データの一部

CX4-H5219-ELISA
CXCR4 ELISA

Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).

Protocol
CX4-H52D3-ELISA
CXCR4 ELISA

Immobilized Human CXCR4 Full Length Protein, Flag,His Tag (Cat. No. CX4-H52D3) at 5 μg/mL (100 μL/well) can bind Human Ulocuplumab, Human IgG4 with a linear range of 0.1-16 ng/mL (QC tested).

Protocol

Synonym Name

CXCR4,CD184,Fusin,D2S201E,FB22,HM89,HSY3RR,LAP3,LCR1,LESTR,NPY3R,NPYR,NPYRL,NPYY3R,WHIM

Background

C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Plerixafor SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 Approved Genzyme Corp Mozobil, Mobozil, 释倍灵 United States Lymphoma, Non-Hodgkin; Multiple Myeloma Genzyme Corp 2008-12-15 Agranulocytosis; Pulmonary Fibrosis; Rejection of organ transplantation; Respiratory Distress Syndrome, Adult; Leukopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Colorectal Neoplasms; Lymphopenia; Multiple Myeloma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Lymphoma; Granulomatous Disease, Chronic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia, Sickle Cell; WHIM syndrome; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Infections; Leukemia, Myelogenous, Chronic; Wiskott-Aldrich Syndrome; Ovarian Neoplasms; Hematologic Neoplasms; Neutropenia; Bone metastases; Warts; Primary Graft Dysfunction; Coronavirus Disease 2019 (COVID-19); Fanconi Anemia; Hodgkin Disease; Pancreatic Neoplasms; Myelodysplastic Syndromes Details
Mavorixafor AMD-11070; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081; X4P-001-IO Approved Genzyme Corp XOLREMDI, Xolremdi United States WHIM syndrome X4 Pharmaceuticals Inc 2024-04-26 HIV Infections; WHIM syndrome; Neutropenia; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma Details
Motixafortide 4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168; 4F-benzoyl-TN-14003 Approved Biokine, Kyoto University APHEXDA United States Hematopoietic stem cell transplantation (HSCT) Biolinerx Ltd 2023-09-08 Leukemia, Myelogenous, Chronic; Hematopoietic stem cell transplantation (HSCT); Esophageal Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Pancreatic Neoplasms; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Adenocarcinoma Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
[68Ga]Pentixafor [68Ga]Ga-PentixaFor; CXCR4-PET; 68Ga-PTF; [68Ga]Ga-PentixaFor PET/CT; [68Ga]Ga-PTF Phase 3 Clinical The University Of Iowa, Pentixapharm AG Lymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Multiple Myeloma; Histiocytosis, Sinus; Erdheim-Chester Disease; Histiocytic Sarcoma; Myocarditis; Lymphoma, Non-Hodgkin; Hyperaldosteronism; Central Nervous System Lymphoma Details
90Y-Pentixather Phase 2 Clinical University Of Wurzburg, Technical University Of Munich Multiple Myeloma; Central Nervous System Lymphoma Details
177Lu-Pentixather Phase 2 Clinical Technical University Of Munich, Nantes University Hospital, University Of Wurzburg Leukemia; Multiple Myeloma Details
Burixafor Hydrobromide TG-0054; GP 01; GPC-100; TG-3000 Phase 2 Clinical TaiGen Biotechnology Co Ltd Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Multiple Myeloma; Prostatic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
MSX-122 Q-122; WZ-40; MSX-122 Phase 2 Clinical Altiris Therapeutics Solid tumours; Hot Flashes Details
PTX-9908 PTX-9908 Phase 2 Clinical Pertinax Therapeutics Carcinoma, Hepatocellular Details
Ga-68-CXCR4 Ga-68-CXCR4 Phase 2 Clinical Koo Foundation Sun Yat-Sen Cancer Center Lymphoma, B-Cell Details
Plerixafor/Tacrolimus Hydrate AMD3100+FK506; MRG-001(MedRegen) Phase 2 Clinical MedRegen LLC Motor Neuron Disease; Cytokine Release Syndrome; Hepatitis, Alcoholic; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis Details
NRP-2945 NRP-2945; NNZ-4945 Phase 2 Clinical Neuren Pharmaceuticals Ltd, Calzada Ltd Angelman Syndrome; Rett Syndrome; Lennox Gastaut Syndrome; Epilepsy, Absence; Epilepsy, Temporal Lobe; Amyotrophic Lateral Sclerosis Details
4-P-021 4P021; 4-P-021 Phase 2 Clinical 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille Coronavirus Disease 2019 (COVID-19) Details
CGT-1881 CGT1881; CGT-1881 Phase 2 Clinical Cgenetech(Suzhou China) Co Ltd Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin Details
AGT 103-T AGT 103-T Phase 1 Clinical American Gene Technologies International Inc HIV Infections Details
Balixafortide POL-6326 Phase 1 Clinical Polyphor Ltd Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell Details
JVS-100 JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 Phase 1 Clinical Cleveland Clinic Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease Details
68Ga-JH12 68Ga-JH12 Phase 1 Clinical First Affiliated Hospital Of Fujian Medical University Neoplasms Details
203-Lead Pentixather Phase 1 Clinical National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center Small Cell Lung Carcinoma; Lung Neoplasms Details
212-Lead Pentixather Phase 1 Clinical National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center Small Cell Lung Carcinoma; Lung Neoplasms Details
68Ga-Pentixather 68Ga-Pentixather Phase 1 Clinical Peking Union Medical College Hospital Multiple Myeloma Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) Phase 1 Clinical Sichuan University Multiple Myeloma Details
AD-214 AD-214 Phase 1 Clinical Adalta Ltd Lung Diseases, Interstitial Details
X-4136 X-4136 Clinical X4 Pharmaceuticals Inc Lymphoma, B-Cell; Melanoma; Uterine Cervical Neoplasms Details
[18F]AlF-NOTA-pentixather Sichuan Provincial People'S Hospital Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap